Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset NGVT

Coverage 166,373 Raw stories ingested 21,862 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,793 Assets with fetched stories

Cryptocurrencies BTC 7,349 ETH 4,859 XRP 3,278 SOL 2,984 HYPE 1,761 USDC 1,589

Stocks NVDA 1,790 SPCX 1,455 MU 1,325 MSFT 1,296 AAPL 1,042 TSLA 1,026

Commodities GOLD 549 SILVER 293 OIL 101 PLATINUM 14 PALLADIUM 4 COPPER 3

Forex EURUSD 498 GBPUSD 378 USDCAD 150 USDJPY 146 AUDUSD 99 USDCHF 63

2,195 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 41s ago
FMP Forex News Fetch every 5 min 2m ago
CoinGecko News Fetch every 5 min 4m ago
FIO Stock News Fetch every 10 min 2m ago
Patria Stock News Fetch every 10 min 2m ago
Editorial rewrite Rewrite every minute 41s ago
Asset sync Assets every 1 hour 21m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-09-08 17:52 1d ago Published 2026-09-08 12:25 1d ago	Ingevity zvýšila výhled EBITDA na 380 až 400 milionů USD Ingevity zvýšila výhled upraveného EBITDA na rok 2026 na 380–400 milionů USD po růstu upraveného EBITDA ve 2. čtvrtletí o 14 % na 115 milionů USD. NGVT Ingevity	FMP Stock News	78
Original source text Key Takeaways Ingevity shares are up 19.2% YTD, supported by portfolio optimization and stronger hybrid demand. Adjusted EBITDA rose 14% to $115 million in Q2, while margin expanded to 36.6%.Ingevity raised 2026 adjusted EBITDA guidance to $380-$400 million amid improved earnings. Ingevity Corporation (NGVT - Free Report) shares have rallied 19.2% year to date. The company has also outperformed the Zacks Chemical - Specialty industry’s 9.1% growth over the same time frame. The rally has been supported by Ingevity’s successful portfolio optimization efforts, stronger demand for higher-value hybrid vehicle applications and pricing initiatives, which have improved earnings and boosted investor confidence in the company’s long-term growth prospects. Image Source: Zacks Investment Research Let’s take a look at the factors that are driving NGVT stock. Portfolio Transformation & Higher Margins Support GrowthIngevity continues to benefit from its efforts to streamline and optimize its portfolio, with a focus on higher-margin businesses and enhancing the quality of its earnings. The company has made considerable progress in this strategy through the divestiture of its Industrial Specialties business, Ozark Materials Road Markings product line and crude tall oil refinery, while the Advanced Polymer Technologies business remains under the divestiture process. The sale of the Ozark Road Markings business for approximately $65 million strengthened the company’s portfolio. Ingevity’s earnings are also supported by strategic acquisitions, including Georgia-Pacific’s pine chemicals business. Cost-reduction initiatives, pricing actions and favorable product mix have further aided profitability. These measures have helped the company mitigate inflationary pressures and maintain an impressive financial performance amid an uncertain macroeconomic backdrop. In the second quarter, adjusted EBITDA climbed 14% year over year to $115 million, while adjusted EBITDA margin expanded to 36.6%. Management also raised its 2026 adjusted EBITDA guidance to $380-$400 million, reflecting confidence in the company’s earnings. The company is also gaining from the increasing penetration of hybrid vehicles. As consumer preferences have shifted toward hybrids, particularly following the expiration of EV tax credits, demand for advanced and higher-value activated carbon solutions has improved. This trend, together with pricing actions and a favorable product mix, has supported sales and profitability in Performance Materials. Management expects the growing adoption of hybrids to develop into a broader global trend, offering lucrative growth potential in the future. Overall, continued portfolio simplification, improving margins, pricing benefits and rising demand for higher-value applications should support Ingevity’s earnings growth and enhance long-term shareholder value. NGVT’s Zacks Rank & Other Key PicksNGVT currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the Basic Materials space are Neo Performance Materials Inc. (NOPMF - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Avient Corporation (AVNT - Free Report) . While NOPMF currently sports a Zacks Rank #1 (Strong Buy), CRS and AVNT carry a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for NOPMF’s 2026 earnings is pegged at $1.4 per share, indicating a 185.71% year-over-year increase. NOPMF’sshares have gained 84.1% over the past year. The Zacks Consensus Estimate for CRS’ fiscal 2027 earnings is pegged at $12.92 per share, indicating a rise of 20.07% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.39%. The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.2 per share, indicating a 13.48% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’s shares have gained 17.4% over the past year.
	Saved 2026-08-31 05:09 9d ago Published 2026-08-26 13:26 14d ago	Ingevity zvýšila výhled upraveného EPS a EBITDA pro rok 2026 Ingevity zvýšila výhled upraveného EPS pro rok 2026 na 5 až 5,45 USD a výhled EBITDA na 380 až 400 milionů USD. Firma zároveň pokračuje v portfoliové transformaci a rozšiřuje nové růstové oblasti. NGVT Ingevity	FMP Stock News	78
Original source text Key Takeaways Ingevity raised its 2026 adjusted EPS outlook to $5-$5.45 and EBITDA forecast to $380-$400 million.Portfolio divestitures and stranded-cost cuts are sharpening Ingevity's focus on higher-return opportunities.PFAS filtration, caprolactone and polyol expansion, and hybrid demand are opening new growth avenues. Ingevity Corporation (NGVT - Free Report) is benefiting from investments in high-return opportunities and development of new growth avenues. We are positive about NGVT’s prospects and believe that the time is right for you to add the stock to the portfolio, as it looks promising and is poised to carry the momentum ahead. Let's see what makes NGVT stock an attractive investment option at the moment. Positive Analyst Sentiment for NGVT StockEarnings estimates for NGVT have been going up over the past 30 days. The Zacks Consensus Estimate for fiscal 2026 has increased by 6.9%. The consensus estimate for fiscal 2027 has also been revised 1.7% upward over the same time frame. The favorable estimate revisions instill investor confidence in the stock. The Zacks Consensus Estimate for NGVT’s 2026 earnings is pegged at $5.40, suggesting a 30.75% increase from the previous year’s tally. Earnings are projected to increase by 9.26% in 2027. Image Source: Zacks Investment Research NGVT’s Superior Return on Equity (ROE)ROE is a measure of a company’s efficiency in utilizing shareholders’ funds. ROE for the trailing 12-months for Ingevity is 284.7%, above the industry’s level of 22.1%. Image Source: Zacks Investment Research Upbeat OutlookIngevity raised its full-year 2026 adjusted earnings guidance to $5-$5.45 per share from the previous projection of $4.7-$5.2. The company also increased its adjusted EBITDA forecast to $380-$400 million from $370-$395 million. The company continues to expect full-year net sales of $1.05-$1.15 billion. Free cash flow is now projected at $220-$245 million, excluding the $113.2 million litigation settlement payment compared with the prior outlook of $215-$245 million. An OutperformerIngevity shares have gained 20.3% against the industry’s decline of 0.9% in the past year. Image Source: Zacks Investment Research Portfolio Transformation and New Growth Platforms Support NGVTIngevity’s ongoing portfolio transformation is improving the prospects of its business and sharpening its focus on higher-return opportunities. The company has completed the divestitures of Industrial Specialties and Road Markings, while the divestiture process for Advanced Polymer Technologies is now progressing steadily. It has also eliminated $10 million of approximately $20 million in stranded costs associated with the divestitures, providing an additional structural cost benefit. The company is also developing newer avenues that could support growth over time. Ingevity secured its first municipal water-treatment contract for PFAS filtration, a significant commercial validation. Its differentiated performance and lower-cost, drop-in potential of its carbon technology address PFAS requirements. The company is also expanding the monomer production capacity of caprolactone in Warrington and increasing the polyol capacity at its DeRidder plant. Meanwhile, the structural shift toward hybrid vehicles is strengthening Ingevity’s Performance Materials segment. Hybrids require more advanced carbon solutions and generate a higher-value product mix, supporting the segment’s long-term competitive positioning. Finally, disciplined capital allocation retains Ingevity’s lucrativeness. Leverage has reached 2.5X, while the company continues to reduce debt and invest in high-return opportunities. Ingevity repurchased $35 million of shares in the second quarter and remains committed to its $300 million repurchase program through 2027, providing an additional tailwind for the stock. NGVT’s Zacks Rank & Other Key PicksNGVT currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the Basic Materials space are Neo Performance Materials Inc. (NOPMF - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Avient Corporation (AVNT - Free Report) . While NOPMF currently sports a Zacks Rank #1 (Strong Buy), CRS and AVNT carry a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for NOPMF’s 2026 earnings is pinned at $1.4 per share, indicating a 185.71% year-over-year increase. NOPMF’sshares have gained 93% over the past year. The Zacks Consensus Estimate for CRS’ fiscal 2027 earnings is pegged at $12.92 per share, indicating a rise of 20.07% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.39%. The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.2 per share, indicating a 13.48% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’sshares have gained 19.6% over the past year.
	Saved 2026-08-06 17:08 1mo ago Published 2026-08-06 11:11 1mo ago	Ingevity zvýšila upravený zisk na akcii i výhled EPS po silném čtvrtletí Ingevity ve 2. čtvrtletí zvýšila upravený zisk na akcii o 42,6 % na 1,74 USD a tržby překonaly odhady na 314,1 mil. USD. Firma zároveň zvedla celoroční výhled upraveného EPS na 5–5,45 USD. NGVT Ingevity	FMP Stock News	92
Original source text Key Takeaways Ingevity's Q2 adjusted EPS rose 42.6% to $1.74, while revenues beat estimates at $314.1 million.Pricing, product mix and higher volumes lifted adjusted EBITDA margin to 36.6% despite lower sales.Ingevity raised 2026 EPS guidance to $5-$5.45 and EBITDA guidance to $380-$400 million. Ingevity Corporation (NGVT - Free Report) reported second-quarter 2026 adjusted earnings of $1.74 per share, up 42.6% year over year and above the Zacks Consensus Estimate of $1.31 by 32.8%. Revenues declined 5.2% to $314.1 million but surpassed the consensus mark of $299.4 million by 4.9%. Excluding the divested Road Markings business, sales rose 5%. Higher pricing, favorable product mix and increased volumes lifted adjusted EBITDA margin to 36.6%. Segmental ReviewPerformance Materials generated net sales of $160.6 million, up 4.4% from $153.9 million in the prior-year quarter. The segment’s EBITDA increased 6.3% year over year to $86.1 million. Higher volumes, improved price and mix, and stronger plant utilization more than offset increased selling, general and administrative and other expenses. The company’s Performance Chemicals operations are now represented by the Pavement Technologies segment following the Road Markings divestiture. Pavement Technologies’ net sales fell 22.4% year over year to $104.2 million, primarily because the Road Markings product line was sold on April 15, 2026. Segment EBITDA declined to $25.4 million from $28.8 million because the prior-year quarter included $6 million of Road Markings EBITDA. Improved pricing and volumes in the remaining business partly offset the lost contribution. Advanced Polymer Technologies posted net sales of $49.3 million, up 13.9% from $43.3 million. Segment EBITDA jumped to $11.2 million from $2 million. Improved product mix and higher plant utilization supported the increase, as the year-ago period included extended downtime related to new boiler installations. FinancialsNet cash used in operating activities was $13.8 million in the second quarter. Free cash flow totaled $89.1 million. NGVT repurchased approximately $35 million of common stock during the quarter at a weighted average price of $70.94 per share. Roughly $211 million remained available under the company’s existing share-repurchase authorization at the end of the period. Net leverage improved to 2.5 times from 3 times in the prior-year quarter and also declined from the first quarter of 2026. Cash and cash equivalents stood at $97.4 million as of June 30, 2026. OutlookIngevity raised its full-year 2026 adjusted earnings guidance to $5-$5.45 per share from the previous projection of $4.7-$5.2. The company also increased its adjusted EBITDA forecast to $380-$400 million from $370-$395 million. The company continues to expect full-year net sales of $1.05-$1.15 billion. Free cash flow is now projected at $220-$245 million, excluding the $113.2 million litigation settlement payment, compared with the prior outlook of $215-$245 million. Ingevity intends to use its projected cash generation to reduce leverage to its long-term target range of 2-2.5 times and return capital to shareholders. NGVT Stock’s Price PerformanceShares of Ingevity have gained 52.7% in a year compared with the industry’s 5.6% growth. Image Source: Zacks Investment Research NGVT’s Rank & Key PicksNGVT currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the basic materials space are Neo Performance Materials Inc. (NOPMF - Free Report) ,Almonty Industries Inc. (ALM - Free Report) and Skeena Resources Limited (SKE - Free Report) . Neo Performance is slated to report second-quarter 2026 results on Aug. 11. The Zacks Consensus Estimate for earnings is pegged at 50 cents per share. NOPMF sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. Almonty is expected to report second-quarter 2026 results on Aug. 13. The Zacks Consensus Estimate for ALM’s second-quarter earnings per share is pegged at 10 cents, indicating 300% year-over-year growth. ALM carries a Zacks Rank #2 (Buy) at present. Skeena is expected to report second-quarter 2026 results on Aug. 13. The consensus estimate for SKE’s loss per share is pegged at 11 cents. SKE presently carries a Zacks Rank #2.
	Saved 2026-07-31 13:23 1mo ago Published 2026-07-31 04:47 1mo ago	Ingevity překonala odhady a zvýšila výhled EPS Ingevity ve 2. čtvrtletí překonala odhady: EPS činil 1,74 USD a tržby 314,1 milionu USD. Firma zároveň zvýšila celoroční výhled upraveného EPS na 5,00 až 5,45 USD. NGVT Ingevity	FMP Stock News	72
Original source text Posted by Defense World Staff on Jul 31st, 2026 Bank of New York Mellon Corp reduced its stake in shares of Ingevity Corporation (NYSE:NGVT – Free Report) by 6.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 211,002 shares of the company’s stock after selling 13,808 shares during the quarter. Bank of New York Mellon Corp owned about 0.60% of Ingevity worth $15,030,000 at the end of the most recent quarter. Several other institutional investors have also recently bought and sold shares of NGVT. Global Retirement Partners LLC acquired a new stake in shares of Ingevity in the 4th quarter valued at $27,000. Meeder Asset Management Inc. acquired a new position in shares of Ingevity during the fourth quarter valued at $33,000. Kestra Advisory Services LLC bought a new position in Ingevity in the fourth quarter valued at about $47,000. Geneos Wealth Management Inc. increased its position in Ingevity by 85.8% in the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after purchasing an additional 387 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in Ingevity in the second quarter worth about $46,000. Institutional investors own 91.59% of the company’s stock. Ingevity Stock Performance Shares of NGVT stock opened at $70.02 on Friday. Ingevity Corporation has a 52 week low of $39.74 and a 52 week high of $79.29. The company has a debt-to-equity ratio of 27.83, a quick ratio of 0.92 and a current ratio of 1.42. The company’s 50 day moving average price is $71.63 and its two-hundred day moving average price is $70.95. The company has a market capitalization of $2.43 billion, a P/E ratio of 47.63 and a beta of 1.16. Ingevity (NYSE:NGVT – Get Free Report) last released its earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.41. Ingevity had a return on equity of 261.97% and a net margin of 4.65%.The firm had revenue of $314.10 million during the quarter, compared to analysts’ expectations of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. On average, analysts expect that Ingevity Corporation will post 5.05 earnings per share for the current fiscal year. Insider Buying and Selling In other news, SVP Terrance M. Dyer sold 496 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $68.49, for a total transaction of $33,971.04. Following the completion of the transaction, the senior vice president directly owned 7,202 shares in the company, valued at $493,264.98. This represents a 6.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.88% of the company’s stock. Key Ingevity News Here are the key news stories impacting Ingevity this week: Positive Sentiment: Quarterly earnings beat expectations. Ingevity reported second-quarter EPS of $1.74, above analyst estimates ranging from $1.31 to $1.33 and up from $1.39 a year earlier. Revenue of $314.1 million also exceeded the $312.2 million consensus estimate. Ingevity Tops Q2 Earnings and Revenue Estimates Positive Sentiment: Full-year 2026 adjusted EPS guidance was raised. The company now expects adjusted EPS of $5.00 to $5.45, above the prior outlook and higher than the roughly $4.95-$5.05 analyst consensus range. Ingevity also increased its full-year adjusted EBITDA outlook following a solid start to the year. Ingevity’s Q2 Adjusted Earnings Increase, Net Sales Decline; 2026 Adjusted EPS Outlook Raised Neutral Sentiment: Revenue guidance remains broadly in line with expectations. Ingevity maintained 2026 revenue guidance of approximately $1.1 billion to $1.2 billion, compared with consensus expectations near $1.1 billion. Ingevity Reports Second Quarter 2026 Financial Results Negative Sentiment: Net sales declined year over year. Although quarterly revenue edged past estimates, the year-over-year sales decline creates concern about underlying demand and may offset some of the benefit from stronger earnings guidance. The company also reported a negative net margin, adding to investor caution. Analyst Upgrades and Downgrades A number of research analysts have issued reports on NGVT shares. Wall Street Zen upgraded shares of Ingevity from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ingevity in a research note on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Ingevity currently has a consensus rating of “Hold” and a consensus target price of $80.00. Read Our Latest Stock Analysis on Ingevity About Ingevity (Free Report) Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods. The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment. Read More Five stocks we like better than Ingevity Microsoft Just Flipped the AI Spending Narrative Overnight Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling? Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter. « PREVIOUS HEADLINEThe Kroger Co. $KR Shares Sold by First Trust Advisors LP NEXT HEADLINE »First Trust Advisors LP Has $13.97 Million Stock Holdings in Clarivate PLC $CLVT
	Saved 2026-07-30 03:44 1mo ago Published 2026-07-29 21:36 1mo ago	Ingevity ve 2. čtvrtletí překonala odhady zisku i tržeb Ingevity (NGVT) ve 2. čtvrtletí překonala odhady zisku i tržeb: EPS činil 1,74 USD a tržby 314,1 milionu USD. NGVT Ingevity	FMP Stock News	78
Original source text Ingevity (NGVT - Free Report) came out with quarterly earnings of $1.74 per share, beating the Zacks Consensus Estimate of $1.31 per share. This compares to earnings of $1.39 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +32.82%. A quarter ago, it was expected that this company would post earnings of $0.84 per share when it actually produced earnings of $1.15, delivering a surprise of +36.9%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Ingevity, which belongs to the Zacks Chemical - Specialty industry, posted revenues of $314.1 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 4.91%. This compares to year-ago revenues of $365.1 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Ingevity shares have added about 25.9% since the beginning of the year versus the S&P 500's gain of 8.5%. What's Next for Ingevity?While Ingevity has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Ingevity was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.64 on $304.7 million in revenues for the coming quarter and $5.05 on $1.12 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Chemical - Specialty is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Linde (LIN - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on July 31. This gas supplier is expected to post quarterly earnings of $4.49 per share in its upcoming report, which represents a year-over-year change of +9.8%. The consensus EPS estimate for the quarter has been revised 0.6% higher over the last 30 days to the current level. Linde's revenues are expected to be $8.96 billion, up 5.5% from the year-ago quarter.
	Saved 2026-07-17 17:50 1mo ago Published 2026-07-17 12:11 1mo ago	Ingevity získala v Německu schválení pro Evotherm P35 Ingevity získala od BASt schválení pro Evotherm P35 k použití v teplé asfaltové směsi v Německu. Testy potvrdily odolnost a dlouhodobý výkon v reálných podmínkách. NGVT Ingevity	FMP Stock News	78
Original source text Key Takeaways Ingevity's Evotherm P35 gained BASt approval for warm-mix asphalt use in Germany.Years of testing confirmed the product's durability and long-term performance under real-world conditions.Bio-based materials support performance and environmental goals in pavement applications. Ingevity Corporation (NGVT - Free Report) announced that its Evotherm P35 warm-mix additive has received approval from BASt, Germany's Federal Highway Research Institute, indicating that it meets the institute’s stringent quality standards. The approval allows the additive to be used in warm-mix asphalt applications and validates it for use in one of Europe's most demanding regulatory environments. The approval follows several years of technical evaluation, performance testing and comparison with conventional hot-mix asphalt. The testing was conducted under real-world traffic and environmental conditions. The results met BASt's durability and long-term performance standards required for use on federal projects in Germany. The certification strengthens Ingevity's position in the European pavement technologies market, where regulatory requirements for infrastructure materials are particularly demanding. It also demonstrates the company's ability to tailor its technologies to meet regional specifications while maintaining high performance standards. Evotherm P35 aligns with Germany's performance, environmental and regulatory priorities, highlighting the company’s formulation expertise and capability to satisfy complex technical requirements. Evotherm P35 incorporates bio-based materials designed to improve performance while supporting environmental objectives, reinforcing the company's Pavement Technologies business. NGVT’s shares have gained 62.8% over the past year compared with the industry’s 3.2% growth. Image Source: Zacks Investment Research NGVT’s Zacks Rank & Key PicksIngevity currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the Basic Materials space are Kronos Worldwide, Inc. (KRO - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Albemarle Corporation (ALB - Free Report) . While KRO and CRS currently sport a Zacks Rank #1 (Strong Buy) each, ALB carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for KRO’s 2026 loss is pinned at 33 cents per share, indicating a 65.63% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in one of the trailing four quarters and missed the remaining three. KROshares have gained 7.1% over the past year. The Zacks Consensus Estimate for CRS’ 2026 earnings is pegged at $10.56 per share, indicating a rise of 41.18% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.95%. The Zacks Consensus Estimate for ALB’s current fiscal-year earnings is pinned at $13.06 per share, indicating a 1,753% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 74.5%. ALB’s shares have gained 55% over the past year.
	Saved 2026-07-07 17:58 2mo ago Published 2026-07-07 12:31 2mo ago	Akcie Ingevity letos vzrostly díky prodeji aktiv a hybridům Akcie Ingevity letos vzrostly o 24,8 % a překonaly 18,1% růst odvětví díky prodeji aktiv, akvizicím a vyšší poptávce po hybridech. Prodej Ozark Road Markings přinesl zhruba 65 mil. USD. NGVT Ingevity	FMP Stock News	72
Original source text Key Takeaways Ingevity shares have surged 24.8% YTD, outperforming the specialty chemicals industry's 18.1% gain.NGVT is streamlining via divestitures, acquisitions and cost cuts to improve margins and earnings quality.NGVT benefits from hybrid demand, boosting activated carbon sales and Performance Materials growth. Ingevity Corporation (NGVT - Free Report) shares have rallied 24.8% year to date. The company has also outperformed the Zacks Chemical - Specialty industry’s 18.1% growth over the same time frame. The rally has been driven by Ingevity's successful portfolio optimization strategy, improving demand for higher-value hybrid vehicle applications and pricing actions that have strengthened earnings growth and reinforced confidence in the company’s long-term growth outlook. Image Source: Zacks Investment Research Let’s take a look at the factors that are driving NGVT stock. Portfolio Optimization & Hybrid Vehicle Demand Drive GrowthIngevity is benefiting from its ongoing portfolio optimization and simplification strategy, which is aimed at sharpening its focus on higher-margin businesses and improving overall earnings quality. The company has made significant progress by divesting its Industrial Specialties business, Ozark Materials Road Markings product line and crude tall oil refinery, while continuing the divestiture process for its Advanced Polymer Technologies business. The company has recently completed the sale of its Ozark Road Markings business for approximately $65 million as part of these initiatives. Additionally, value-creating acquisitions such as Georgia-Pacific’s pine chemicals business have driven earnings and revenue growth. The company has also undertaken actions to lower costs and boost profitability. The ability of NGVT to offset inflation through pricing power also enabled solid financial results despite an uncertain macroeconomic environment. Alongside the portfolio transformation actions, Ingevity is benefiting from the adoption of hybrid vehicles. Following the expiration of EV tax credits, consumer preference has shifted toward hybrids, which has increased the long-term role of advanced and higher-value activated carbon solutions. This favorable product mix, combined with pricing actions, drove higher sales and stronger margins in Ingevity’s strongest segment, Performance Materials. Management also expects the transition toward hybrids to become a broader global trend, creating a long-term growth opportunity for its high-margin Performance Materials business. Together, the company's strategic portfolio optimization and increasing exposure to higher-value hybrid vehicle applications position it for stronger earnings growth, improved profitability and sustainable shareholder value creation. NGVT’s Zacks Rank & Other Key PicksNGVT currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the Basic Materials space are Albemarle Corporation (ALB - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Avino Silver & Gold Mines Ltd. (ASM - Free Report) . While ALB sports a Zacks Rank #1 (Strong Buy) at present, CRS and ASM carry a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for ALB’s 2026 earnings is pinned at $12.98 per share, indicating a 1,743.04% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed one, with an average surprise of 74.5%. ALB’s shares have jumped 90.5% over the past year. The Zacks Consensus Estimate for CRS’ 2026 earnings is pegged at $10.56 per share, indicating a rise of 41.18% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.95%. The Zacks Consensus Estimate for ASM’s current fiscal-year earnings is pinned at 34 cents per share, indicating a 17.24% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 125%. ASM’sshares have gained 86.4% over the past year.